

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

M.10749 - PAI PARTNERS / THE CARLYLE GROUP / THERAMEX

SECTION 1.2

Description of the concentration

1. On 20 June 2022, the Commission has received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) N°139/2004 (EUMR), by which funds managed by PAI Partners S.à.r.l, a wholly-owned subsidiary of PAI Partners SAS (together with all its affiliates and controlled subsidiaries, “**PAI Partners**”) and by CEP V Participations S.à.r.l. SICAR (“**CEP V**”), which is controlled by funds managed by The Carlyle Group, Inc. (together with its controlled funds and affiliates, “**Carlyle**”) will acquire joint control of Theramex Healthcare Topco Limited and its direct and indirect, wholly-owned subsidiaries (“**Theramex**”) within the meaning of Articles 3(1)(b) of the EUMR.
 - i. PAI Partners is a private equity firm, headquartered in Paris, France, that manages a number of funds investing in the business services, food & consumer, general industrials, and healthcare sectors. Through its controlled portfolio companies, PAI Partners generates revenue in many countries worldwide, notably in all EU Member States.
 - ii. Carlyle is a global alternative asset manager, which manages funds that invest globally across three investment disciplines: (i) Global Private Equity (including corporate private equity, real estate and natural resources funds); (ii) Global Credit (including liquid credit, illiquid credit and real assets credit); and (iii) Investment Solutions (private equity fund of funds program, which include primary fund, secondary and related co-investment activities).
 - iii. Theramex is a global specialty pharmaceutical company dedicated to women’s health, which focuses on contraception, fertility, menopause and osteoporosis. The company markets a broad range of innovative, branded and branded generic products across numerous countries around the world. Theramex is active in 25 EU Member States.